What is SanRx?

SanRx was founded in 2004 by an experienced scientific and business team, including strong scientific advisors and internationally renowned scientific collaborators. Their contributors are published in key scientific publications.

What are Calcium Pterins?

Calcium Pterins are a proprietary family of novel, non-toxic, oral immunomodulators that can potentially treat cancer, infectious disease, neurological diseases, and arthritis. They are covered by global patents (filed 1995-2007).

Pterins (from the Greek pteron = wing) are naturally-occurring heterocyclic compounds responsible for the vibrant color of butterfly wings. SanRx products are made from synthetic versions.

Calcium Pterins are non toxic as they are comprised of calcium and pterin, both of which are part of human chemistry.

How were they discovered?

In the 1970's while at UCLA, a research team joined by Dr. Moheno consistently observed a fluorescent blue spot in the chromatograms of urine from cancer patients. The blue spot was determined to be pterin-6-aldehyde. Several pterins were subsequently shown by high pressure liquid chromatography (HPLC) to have altered concentrations in the urine of cancer patients.

What does Calcium Pterin do?

Normally, the immune system recognizes cancer cells, which can escape the immune system through the Indoleamine 2,3-Dioxygenase (IDO) pathway. Calcium Pterins have been shown to inhibit IDO, which is a feedback inhibitor of Th1 Inflammatory Immune Response. Inhibiting IDO means that the cancer cells cannot escape the immune system in this way.

Search of scientific literature revealed some pterins possess anti-tumor and immuno-modulatory properties. Study of the chemistry of "active" pterins led to successful testing of calcium pterin for antitumor activity. Further refinement of the calcium pterin structure led to the synthesis DCP, a second active pterin, by Dr. Wolfgang Pfleiderer, and to the in vivo testing and patenting of DCP by SanRx.

What conditions may be treated by Calcium Pterins?

Successful published animal model testing has been carried out against:

• Breast Cancer

• Infectious diseases (Hepatitis B)

These other IDO disorders are potentially target indications:

• Neurodegenerative disorders (e.g., major depression, Alzheimer's)

• Arthritis

Why is SanRx different?

SanRx is different because their products are oral and without toxic side-effects, like hair loss and nausea.

As of 2011, there were no approved products in the IDO Modulators category, making SanRx potentially the first in this class.

Xeloda is the one of the few oral products used in Breast Cancer, but with only 15-28% effectiveness.

Selective Estrogen Receptor Modulators (SERMs) like Tamoxifen (oral) is only effective in treating estrogen receptor-positive breast cancers and tumors have shown to develop resistance.

Is SanRx interested in Investors?

SanRx's Opportunity

SanRx was issued a patent on February 16, 2010 for DCP as a compound. DCP is one of over one-hundred complexes pterin compounds that have been patented by SanRx. Broad, offensive-type, composition of matter, methods of use, and pharmaceutical composition patents have been issued for these compounds. DCP is very inexpensive to manufacture, and initial estimates indicate the cost will be very low, perhaps less than 50 cents a dose.

The current size of the global therapeutics market for breast cancer is $5 billion per year. Many of the therapeutic drugs have limited and temporary positive effects but still produce hundreds of millions of dollars for their drug companies. A number of new therapeutics have been introduced in the last ten years that are used in combination with other drugs for breast cancer. These treatments are generally based on reducing tumor growth through the blocking of estrogen, progesterone, HER2 sites (receptor sites linked to a form of cancer), and microtubule functions. Without question, DCP, once proven in human trials, would be used to supplement these current therapies or replace them altogether in many cases.

SanRx Market

Initially, DCP will be introduced as a drug to be used in conjunction with existing drugs for patients with advanced metastatic breast cancer. Later, we will target its use for treatment in earlier stages of the disease. SanRx plans to market DCP to oncologists as a prescription drug for oral dosage. The initial target markets will be the U.S. and Japan, with the rest of the world following. SanRx intends to commercialize its drugs through partnerships with pharmaceutical leaders in each region.

SanRx expects to process DCP quickly through FDA trials, with approval in Q4 2011. Because of the number of breast cancer deaths per year, we expect a fast track status for human testing. The fact that pterin is a natural body compound is expected to help streamline the FDA approval process.

Please contact us for information on investing in this breakthrough technology.